Alector Inc.
Clinical trials sponsored by Alector Inc., explained in plain language.
-
Alzheimer's drug trial extension halted after safety monitoring
Disease control TerminatedThis study aimed to evaluate the long-term safety and effectiveness of the experimental drug AL002 in people with early Alzheimer's disease. It was an extension study for 197 participants who had completed a previous AL002 trial. The study was terminated, and its primary focus wa…
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Halted trial tests potential treatment for genetic form of dementia
Disease control TerminatedThis study tested an investigational drug called AL001 for people who have or are at risk for frontotemporal dementia (FTD) because they carry a specific gene mutation. The goal was to see if the drug could slow or control the progression of the disease. The trial was a large Pha…
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
Brain disease drug trial halted after offering continued treatment
Disease control TerminatedThis study aimed to provide continued access to the experimental drug latozinemab for people with neurodegenerative brain diseases who had already taken it in a previous trial. It was designed to monitor the safety of longer-term treatment. The study was terminated and only enrol…
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC